These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 691928)

  • 1. [Treatment of essential hypertension with pindolol].
    Kocemba J; Kawecka-Jaszcz K; Sniezek M; Starzycka M; Augustyński W
    Kardiol Pol; 1978; 21(3):201-8. PubMed ID: 691928
    [No Abstract]   [Full Text] [Related]  

  • 2. [A controlled clinical therapeutic trial of prindolol in patients with arterial hypertension (author's transl)].
    Marinković M; Winter-Fudurić ; Kuzmanić D
    Lijec Vjesn; 1976 Apr; 98(4):172-6. PubMed ID: 787710
    [No Abstract]   [Full Text] [Related]  

  • 3. Haemodynamic effects of pindolol in essential hypertension with special reference to resistance vessels in the forearm during maximal vasodilatation.
    Gretzer I; Dunér H; Lagerbäck B
    J Hypertens Suppl; 1985 Dec; 3(3):S215-7. PubMed ID: 2856707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prolonged antihypertensive effect of beta-adrenolytic treatment with Visken in patients with essential hypertension].
    Lukasik S; Halawa B; Surowiak M; Kasprzak J
    Pol Tyg Lek; 1977 Nov; 32(47):1837-9. PubMed ID: 341096
    [No Abstract]   [Full Text] [Related]  

  • 5. [Haemodynamic effect of short-term adrenergic block with prindolol at rest and during strain in hypertonic subjects (stage II)].
    Ressl J; Chrástek J; Jandová R; Nhon TQ
    Cas Lek Cesk; 1974 Oct; 113(43):1317-21. PubMed ID: 4429976
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of visken and hypothiazide on the indices of the central and renal hemodynamics in patients with atherosclerotic hypertension].
    Shishkina OS
    Vrach Delo; 1990 Apr; (4):41-3. PubMed ID: 2275163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)].
    Persson I; Ulrich J
    Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of essential hypertension with prindolol].
    Kuska J; Sledzinski Z; Kokot F
    Wiad Lek; 1977 Apr; 30(7):505-10. PubMed ID: 855327
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of the treatment with propranolol and pindolol on selected hemodynamic parameters in patients with primary arterial hypertension].
    Trojnar R; Markiewicz M; Rymar B; Wysokiński A
    Wiad Lek; 1989 Aug 15-Sep 15; 42(16-18):929-34. PubMed ID: 2701039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term treatment of essential hypertension using a beta-receptor blockader: effect on total-body-potassium and exchangeable sodium].
    Brecht HM; Werner E; Vlachoyannis J; Bechstein PB; Schoeppe W
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1329-32. PubMed ID: 1029992
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of treatment with pindolol (Visken) on hemodynamics in patients with primary hypertension].
    Wyrzykowski B; Suchecka-Rachoń K
    Kardiol Pol; 1986; 29(4):285-91. PubMed ID: 3537436
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of essential hypertension with pindolol and clopamide: problems arising from a combined beta blocker and diuretic therapy.
    Rosenfeld JB; Traub YM; Cohen L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):786-97. PubMed ID: 4217245
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the therapeutic efficacy of a fixed combination of beta blockader and diuretic, in the treatment of systemic arterial hypertension. A multicenter study].
    Zilenovski AM; Freire CA; Iverson MT
    Arq Bras Cardiol; 1984 Jun; 42(6):435-41. PubMed ID: 6393921
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of hypertension with the beta-receptor-antagonist pindolol (Viskèn). A comparison with chlorthalidone (Hygroton)].
    Schaffalitzky de Muckadel ; Gyntelberg F
    Ugeskr Laeger; 1973 May; 135(20):971-4. PubMed ID: 4585570
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hemodynamic long-term effects of a beta-receptor blockader (Pindolol) in primary essential hypertension].
    Klein WW; Brandt D; Fluch N; Goebel R; Holzer H; Pöch G
    Adv Clin Pharmacol; 1976; 11():79-85. PubMed ID: 1032573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of visken in hypertension associated with ischemic heart disease and nutritional obesity].
    Khomenko VL; Vasiuk IuA; Romashkin AV; Sivkov SI; Mel'nikov AIu; Buskin VD
    Sov Med; 1990; (3):64-7. PubMed ID: 2195673
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pindolol in benign essential hypertension. A group study by 12 Zürich internists].
    Rhomberg F; Bächtold H; Danczkay I; Hugentobler F; Jaccard G; Kälin R; Pugatsch I; Stauffenegger M; Veraguth F; Waldvogel W
    Schweiz Med Wochenschr; 1979 Jun; 109(26):990-4. PubMed ID: 462166
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ambulatory treatment of so-called "essential" arterial hypertension with pindolol. Short-term study].
    Reffo GC; Pitzorno G; Perin S; Forattini C
    Minerva Med; 1980 Jan; 71(1):49-54. PubMed ID: 6101911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pindolol on blood parathyroid hormone concentration.
    Shasha SM; Ben Aryeh H; Shiller M; Bernheim J
    Isr J Med Sci; 1981 Dec; 17(12):1189-90. PubMed ID: 7327921
    [No Abstract]   [Full Text] [Related]  

  • 20. [M-mode echocardiographic evaluation of antihypertensive efficacy and the mechanism of action of pindolol].
    Bissoli GS; La Canna G; Zanini R; Caobelli A; Berra P; Ettori F; Arosio G
    Minerva Cardioangiol; 1985 Jun; 33(6):337-43. PubMed ID: 4047421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.